Abstract:Non-steroidal anti-inflammatory drugs NSAIDs are widely used for managing various conditions including pain, inflammation, arthritis and many musculoskeletal disorders. NSAIDs exert their biological effects by inhibiting the cyclooxygenase (COX) enzyme, which has two main isoforms COX-1 and COX-2. The COX-2 isoform is believed to be directly related to inflammation. Based on structure-activity relationship (SAR) studies of known selective COX-2 inhibitors, our aim is to design and synthesize a novel series of 2-benzamido-N-(4-substituted phenyl)thiophene-3-carboxamide derivatives. These derivatives are intended to be selective COX-2 inhibitors through structural modification of diclofenac and celecoxib. The compound 2-benzamido-5-ethyl-N-(4-fluorophenyl)thiophene-3-carboxamide VIIa demonstrated selective COX-2 inhibition with an IC50 value of 0.29 μM and a selectivity index 67.24. This is compared to celecoxib, which has an IC50 value of 0.42 μM and a selectivity index 33.8. Molecular docking studies for compound VIIa displayed high binding affinity toward COX-2. Additionally, the suppression of protein denaturation with respect to albumin was performed as an indicative measure of the potential anti-inflammatory efficacy of the novel compounds. Compound VIIa showed potent anti-inflammatory activity with 93% inhibition and an IC50 value 0.54 μM. In comparison, celecoxib achieved 94% inhibition with an IC50 value 0.89 μM. Although molecule VIIa demonstrated significant in vitro anti-inflammatory activity, adhered to Lipinski's "five rules" (RO5) and exhibited promising drug-like properties, it showed indications of poor in vivo activity. This limitation is likely due to poor aqueous solubility, which impacts its bioavailability. This issue could be addressed by incorporating the drug in niosomal nanocarrier. Niosomes were prepared using the thin-film hydration technique. These niosomes exhibited a particle size of less than 200 nm, high entrapment efficiency, and an appropriate drug loading percentage. Transmission electron microscopy (TEM) and differential scanning calorimetry (DSC) studies revealed that the niosomes were spherical and demonstrated compatibility of all of its components. The drug release study indicated that the pure drug had limited practicality for in vivo use. However, incorporating the drug into niosomes significantly improved its release profile, making it more suitable for practical use.

Characterization of solid-state forms of celecoxib

Crystal Form of Celecoxib: Preparation, Characterization and Dissolution

Effect of processing on Celecoxib and its solvates

Ternary Solid Dispersion of Celecoxib Produced by the Solvent Method with Improved Solubility and Dissolution Properties

Preparation of celecoxib tablet by hot melt extrusion technology and application of process analysis technology to discriminate solubilization effect

In vitro characterization of elementary osmotic tablet containing celecoxib

Formulation, optimization, and characterization of whey protein isolate nanocrystals for celecoxib delivery

Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier

Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate

Screening, Synthesis, and Characterization of a More Rapidly Dissolving Celecoxib Crystal Form

Development of a selective COX-2 inhibitor: from synthesis to enhanced efficacy via nano-formulation

Different or the same? exploring the physicochemical properties and molecular mobility of celecoxib amorphous forms

A Novel Cocrystal Approach Celecoxib with Piperine: Simultaneously Enhance Dissolution Rate and Compressibility

Research on Ternary Solid Dispersions of Celecoxib with Surfactant: Preparation, Characterization, and Solubility Property

Solubility enhancement of Cox-2 inhibitors using various solvent systems

Boost of solubility and supersaturation of celecoxib via synergistic interactions of methacrylic acid-ethyl acrylate copolymer (1:1) and hydroxypropyl cellulose in ternary amorphous solid dispersions

Preparation and In Vitro/Vivo Evaluation of New Celecoxib Solid Dispersions with Co-Carrier Containing Aerosil and Poloxamer 188

Celecoxib-hydroxypropyl-β-cyclodextrin inclusion complex in a chitosan/PEO-PPO-PEO block copolymer matrix: Structural effect and drug release

Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation

The effect of some acrylic polymers on dissolution of celecoxib solid dispersion formulations

Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential